CRIS
CurisยทNASDAQ
--
--(--)
--
--(--)
CRIS Profile
Curis, Inc.
A biotechnology company that developing innovative therapeutics for the treatment of cancer
128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421
--
Curis, Inc., was incorporated as a Delaware corporation in February 2000. The company is a biotechnology company focused on the development of emavusertib, an oral small molecule IRAK4 and FLT3 inhibitor, for the treatment of certain lymphomas, leukemias and myeloid diseases. The drug candidate is currently undergoing clinical studies and has received orphan drug designation for multiple indications.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
